Postoperative radiotherapy in resected non-small cell lung cancer: The never-ending story

被引:5
作者
Serrano, Javier [1 ]
Crespo, Patricia Calvo [2 ]
Taboada, Begona [2 ]
Gonzalez, Ana Alvarez [3 ]
Garcia, Rafael Garcia [4 ]
Caamano, Antonio Gomez [5 ]
Reyes, Juan Carlos Trujillo [6 ]
Mielgo-Rubio, Xabier [7 ]
Counago, Felipe [8 ]
机构
[1] Clin Univ Navarra, Dept Radiat Therapy, Calle Marquesado de Santa Marta 1, Madrid 28027, Spain
[2] Hosp Clin Univ Santiago de Compostela, Dept Radiat Oncol, Santiago De Compostela 15706, Spain
[3] HGU Gregorio Maranon, Dept Radiat Oncol, Madrid 28007, Spain
[4] Hosp Ruber Int, Dept Radiat Oncol, Madrid 28034, Spain
[5] Hosp Clin Univ Santiago de Compostela, Dept Radiat Oncol, La Coruna 15706, Spain
[6] Hosp Santa Creu & Sant Pau, Dept Thorac Surg, Barcelona 08026, Spain
[7] Hosp Univ Fdn Alcorcon, Dept Med Oncol, Madrid 28922, Spain
[8] Univ Europea Madrid, Dept Radiat Oncol, Hosp Univ Quironsalud Madrid, Hosp La Luz, Madrid 28223, Spain
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 12卷 / 10期
关键词
Non-small lung cancer; Radiotherapy; Postoperative; Lung cancer; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; MICROSCOPIC RESIDUAL DISEASE; ADJUVANT RADIATION-THERAPY; TARGET VOLUME DEFINITION; AMERICAN SOCIETY; RISK-FACTORS; STAGE-II; SURVIVAL; CHEMOTHERAPY; PNEUMONITIS;
D O I
10.5306/wjco.v12.i10.833
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This manuscript collects in a joint and orderly manner the existing evidence at the present time about postoperative treatment with radiotherapy in non-small cell lung cancer. It also systematically reviews the current evidence, the international recommendations in the most relevant guidelines, the most controversial aspects in clinical and pathological staging, the specific technical aspects of radiotherapy treatment, and also collects all the potential risk factors that have been postulated as significant in the prognosis of these patients, evaluating the possibility of segmenting a particularly sensitive subpopulation with a high risk of relapse on which an adjuvant treatment with radiotherapy could have an impact on their clinical evolution. Finally, currently active trials that aspire to provide more evidence on this topic are reviewed.
引用
收藏
页码:833 / 844
页数:12
相关论文
共 58 条
  • [1] Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: Subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial
    Bennouna, Jaafar
    Senellart, Helene
    Hiret, Sandrine
    Vaissiere, Nathalie
    Douillard, Jean-Yves
    [J]. LUNG CANCER, 2011, 74 (01) : 30 - 34
  • [2] Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis
    Billiet, Charlotte
    Decaluwe, Herbert
    Peeters, Stephanie
    Vansteenkiste, Johan
    Dooms, Christophe
    Haustermans, Karin
    De Leyn, Paul
    De Ruysscher, Dirk
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 110 (01) : 3 - 8
  • [3] Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma
    Boonyawan, Keeratikarn
    Gomez, Daniel R.
    Komaki, Ritsuko
    Xu, Yujin
    Nantavithya, Chonnipa
    Allen, Pamela K.
    Mohan, Radhe
    Liao, Zhongxing
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (04): : 919 - 926
  • [4] Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer
    Boyce-Fappiano, David
    Nguyen, Quynh-Nhu
    Chapman, Bhavana, V
    Allen, Pamela K.
    Gjyshi, Olsi
    Pezzi, Todd A.
    De, Brian
    Gomez, Daniel
    Lin, Steven H.
    Chang, Joe Y.
    Liao, Zhongxing
    Lee, Percy
    Gandhi, Saumil J.
    [J]. CLINICAL LUNG CANCER, 2021, 22 (05) : E745 - E755
  • [5] PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation - study protocol for a randomized controlled trial
    Buetof, R.
    Simon, M.
    Loeck, S.
    Troost, E. G. C.
    Appold, S.
    Krause, M.
    Baumann, M.
    [J]. TRIALS, 2017, 18
  • [6] Burdett S, 1998, LANCET, V352, P257
  • [7] When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
    Cerfolio, Robert James
    Bryant, Ayesha S.
    [J]. ANNALS OF THORACIC SURGERY, 2007, 84 (04) : 1092 - 1097
  • [8] Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
    Chun, Stephen G.
    Hu, Chen
    Choy, Hak
    Komaki, Ritsuko U.
    Timmerman, Robert D.
    Schild, Steven E.
    Bogart, Jeffrey A.
    Dobelbower, Michael C.
    Bosch, Walter
    Galvin, James M.
    Kavadi, Vivek S.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Clifford G.
    Wynn, Raymond B.
    Raben, Adam
    Augspurger, Mark E.
    MacRae, RobertM.
    Paulus, Rebecca
    Bradley, Jeffrey D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 56 - +
  • [9] Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non-Small-Cell Lung Cancer Using the National Cancer Database
    Corso, Christopher D.
    Rutter, Charles E.
    Wilson, Lynn D.
    Kim, Anthony W.
    Decker, Roy H.
    Husain, Zain A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 148 - 155
  • [10] European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer
    De Ruysscher, Dirk
    Faivre-Finn, Corinne
    Moeller, Ditte
    Nestle, Ursula
    Hurkmans, Coen W.
    Le Pechoux, Cecile
    Belderbos, Jose
    Guckenberger, Matthias
    Senan, Suresh
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 124 (01) : 1 - 10